790710-81-5

Basic information

• Product Name: ethyl 8-bromo-6-fluoro-4-oxo-4H-chromene-2-carboxylate
• Synonyms: ethyl 8-bromo-6-fluoro-4-oxo-4H-chromene-2-carboxylate
• CAS NO: 790710-81-5
• Molecular Weight: 315.096
• Mol File: 790710-81-5.mol

Chemical Properties

• CAS DataBase Reference: ethyl 8-bromo-6-fluoro-4-oxo-4H-chromene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 8-bromo-6-fluoro-4-oxo-4H-chromene-2-carboxylate(790710-81-5)
• EPA Substance Registry System: ethyl 8-bromo-6-fluoro-4-oxo-4H-chromene-2-carboxylate(790710-81-5)

Safety Data

• Hazardous Substances Data: 790710-81-5(Hazardous Substances Data)

Upstream product

• 480439-44-9 1-acetoxy-2-bromo-4-fluorobenzene 
• 393-62-4 1-(3-bromo-5-fluoro-2-hydroxyphenyl)ethan-1-one 
• 64-17-5 ethanol 
• 496-69-5 2-bromo-4-fluoro-phenol 
• 1064539-49-6 (EZ)-2-(2-bromo-4-fluorophenoxy)-2-butenedioic acid 

Downstream Products

• 790710-83-7 1-[5-fluoro-2-hydroxy-3-(4-methylpiperazin-1-yl)phenyl]ethanone 

Relevant articles and documents

NOVEL AMINATION PROCESS

Provided herein are novel processes for the preparation of intermediates that may be useful in the preparation of 5-Ht1b receptor antagonist useful in the treatment of depression, anxiety and other related diseases. The present processes may of

NOVEL PROCESS

Provided herein are novel processes for the preparation of intermediates that may be useful in the preparation of 5-Ht1b receptor antagonist useful in the treatment of depression, anxiety and other related diseases. The present processes may offer improve

Successful development and scale-up of a palladium-catalysed amination process in the manufacture of ZM549865

Key steps in the synthesis of ZM549865 (a 5-HT receptor antagonist) are the palladium-catalysed amination of ethyl 8-bromo-6-fluoro-4-oxo-4H-2- chromenecarboxylate and subsequent hydrolysis of the ester group. The development of a simple, robust process c

THERAPEUTIC CHROMONE COMPOUNDS

Provided herein is a compound of the formula (I) wherein said compound is useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating, disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B antagonists. Also provided herein are processes for making compounds of Formula (I) and intermediate compounds.

Therapeutic chroman compounds

Provided herein is a compound represented by the Formula (I) wherein said compounds are useful for the treatment of migraine. Also provided are processes for the preparation of compounds of Formula (I) and intermediates.

Therapeutic heterocyclic compounds

Provided herein is a compound having the formula (I): Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.